FDA authorizes REGEN-COV for COVID-19 prevention in certain individuals; baricitinib without remdesivir
The Food and Drug Administration Friday authorized using the monoclonal antibody therapy REGEN-COV for prevention in certain children and adults who are not fully vaccinated against COVID-19 or not expected to mount an adequate immune response to vaccination.
FDA also authorized administering baricitinib (Olumiant) by itself to treat COVID-19 in hospitalized patients age 2 and older who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. The emergency use authorization previously required administering baricitinib with remdesivir (Veklury).
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…